ALB and chronic kidney disease: The currently ongoing CONFIDENCE trial (NCT05254002) will evaluate the effectiveness of combining finerenone with empagliflozin in individuals with both CKD and T2DM, using a urinary albumin-to-creatinine ratio endpoint.